525 related articles for article (PubMed ID: 24960177)
1. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice.
Terami N; Ogawa D; Tachibana H; Hatanaka T; Wada J; Nakatsuka A; Eguchi J; Horiguchi CS; Nishii N; Yamada H; Takei K; Makino H
PLoS One; 2014; 9(6):e100777. PubMed ID: 24960177
[TBL] [Abstract][Full Text] [Related]
2. Dapagliflozin Does Not Protect against Adriamycin-Induced Kidney Injury in Mice.
Cha JJ; Park HJ; Yoo JA; Ghee J; Cha DR; Kang YS
Kidney Blood Press Res; 2024; 49(1):81-90. PubMed ID: 38185119
[TBL] [Abstract][Full Text] [Related]
3. SHR3824, a novel selective inhibitor of renal sodium glucose cotransporter 2, exhibits antidiabetic efficacy in rodent models.
Yan PK; Zhang LN; Feng Y; Qu H; Qin L; Zhang LS; Leng Y
Acta Pharmacol Sin; 2014 May; 35(5):613-24. PubMed ID: 24786232
[TBL] [Abstract][Full Text] [Related]
4. Central administration of Dapagliflozin alleviates a hypothalamic neuroinflammatory signature and changing tubular lipid metabolism in type 2 diabetic nephropathy by upregulating MCPIP1.
Da J; Xu Y; Tan Y; Zhang J; Yu J; Zhao J; Da Q; Yu F; Zha Y
Biomed Pharmacother; 2023 Dec; 168():115840. PubMed ID: 37931516
[TBL] [Abstract][Full Text] [Related]
5. Dapagliflozin attenuates renal fibrosis by suppressing angiotensin II/TGFβ signaling in diabetic mice.
Jiang M; Yang Z; Lyu L; Shi M
J Diabetes Complications; 2024 Feb; 38(2):108687. PubMed ID: 38266571
[TBL] [Abstract][Full Text] [Related]
6. Sodium-glucose cotransporter 2 inhibition suppresses HIF-1α-mediated metabolic switch from lipid oxidation to glycolysis in kidney tubule cells of diabetic mice.
Cai T; Ke Q; Fang Y; Wen P; Chen H; Yuan Q; Luo J; Zhang Y; Sun Q; Lv Y; Zen K; Jiang L; Zhou Y; Yang J
Cell Death Dis; 2020 May; 11(5):390. PubMed ID: 32444604
[TBL] [Abstract][Full Text] [Related]
7. Gut Microbiota-Tryptophan Metabolism-GLP-1 Axis Participates in β-Cell Regeneration Induced by Dapagliflozin.
Jiang Y; Yang J; Xia L; Wei T; Cui X; Wang D; Jin Z; Lin X; Li F; Yang K; Lang S; Liu Y; Hang J; Zhang Z; Hong T; Wei R
Diabetes; 2024 Jun; 73(6):926-940. PubMed ID: 38471012
[TBL] [Abstract][Full Text] [Related]
8. SGLT2 inhibitor dapagliflozin protects the kidney in a murine model of Balkan nephropathy.
Oe Y; Kim YC; Sidorenko VS; Zhang H; Kanoo S; Lopez N; Goodluck HA; Crespo-Masip M; Vallon V
Am J Physiol Renal Physiol; 2024 Feb; 326(2):F227-F240. PubMed ID: 38031729
[TBL] [Abstract][Full Text] [Related]
9. A PAI-1 mutant, PAI-1R, slows progression of diabetic nephropathy.
Huang Y; Border WA; Yu L; Zhang J; Lawrence DA; Noble NA
J Am Soc Nephrol; 2008 Feb; 19(2):329-38. PubMed ID: 18216319
[TBL] [Abstract][Full Text] [Related]
10. SGLT2 inhibitors therapy protects glucotoxicity-induced β-cell failure in a mouse model of human KATP-induced diabetes through mitigation of oxidative and ER stress.
Shyr ZA; Yan Z; Ustione A; Egan EM; Remedi MS
PLoS One; 2022; 17(2):e0258054. PubMed ID: 35180212
[TBL] [Abstract][Full Text] [Related]
11. Lack of renoprotective effects of targeting the endothelin A receptor and (or) sodium glucose transporter 2 in a mouse model of Type 2 diabetic kidney disease.
Stuart D; Peterson CS; Hu C; Revelo MP; Huang Y; Kohan DE; Ramkumar N
Can J Physiol Pharmacol; 2022 Aug; 100(8):763-771. PubMed ID: 35531905
[TBL] [Abstract][Full Text] [Related]
12. Impact of sodium glucose linked cotransporter-2 inhibition on renal microvascular oxygen tension in a rodent model of diabetes mellitus.
Hare GMT; Zhang Y; Chin K; Thai K; Jacobs E; Cazorla-Bak MP; Nghiem L; Wilson DF; Vinogradov SA; Connelly KA; Mazer CD; Evans RG; Gilbert RE
Physiol Rep; 2021 Jun; 9(12):e14890. PubMed ID: 34184431
[TBL] [Abstract][Full Text] [Related]
13. Effect of dapagliflozin alone and in combination with insulin in a rat model of type 1 diabetes.
Sayed N; Abdalla O; Kilany O; Dessouki A; Yoshida T; Sasaki K; Shimoda M
J Vet Med Sci; 2020 Apr; 82(4):467-474. PubMed ID: 32161237
[TBL] [Abstract][Full Text] [Related]
14. Impacts of Diabetes and an SGLT2 Inhibitor on the Glomerular Number and Volume in db/db Mice, as Estimated by Synchrotron Radiation Micro-CT at SPring-8.
Takiyama Y; Sera T; Nakamura M; Ishizeki K; Saijo Y; Yanagimachi T; Maeda M; Bessho R; Takiyama T; Kitsunai H; Sakagami H; Fujishiro D; Fujita Y; Makino Y; Abiko A; Hoshino M; Uesugi K; Yagi N; Ota T; Haneda M
EBioMedicine; 2018 Oct; 36():329-346. PubMed ID: 30322799
[TBL] [Abstract][Full Text] [Related]
15. Dapagliflozin alleviates renal inflammation and protects against diabetic kidney diseases, both dependent and independent of blood glucose levels.
Cai A; Shen J; Yang X; Shao X; Gu L; Mou S; Che X
Front Immunol; 2023; 14():1205834. PubMed ID: 38022502
[TBL] [Abstract][Full Text] [Related]
16. Protective Effects of Ethanolic Extract from Rhizome of
Yoon JJ; Park JH; Lee YJ; Kim HY; Han BH; Jin HG; Kang DG; Lee HS
Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281284
[TBL] [Abstract][Full Text] [Related]
17. Dapagliflozin Does Not Directly Affect Human α or β Cells.
Dai C; Walker JT; Shostak A; Bouchi Y; Poffenberger G; Hart NJ; Jacobson DA; Calcutt MW; Bottino R; Greiner DL; Shultz LD; McGuinness OP; Dean ED; Powers AC
Endocrinology; 2020 Aug; 161(8):. PubMed ID: 32428240
[TBL] [Abstract][Full Text] [Related]
18. Dapagliflozin Alleviates Diabetic Kidney Disease
Wang YH; Chang DY; Zhao MH; Chen M
Antioxid Redox Signal; 2024 Mar; 40(7-9):492-509. PubMed ID: 37276148
[No Abstract] [Full Text] [Related]
19. Sodium glucose cotransporter 2 inhibition in the diabetic kidney: an update.
Novikov A; Vallon V
Curr Opin Nephrol Hypertens; 2016 Jan; 25(1):50-8. PubMed ID: 26575393
[TBL] [Abstract][Full Text] [Related]
20. Sodium glucose transporter-2 inhibition has no renoprotective effects on non-diabetic chronic kidney disease.
Ma Q; Steiger S; Anders HJ
Physiol Rep; 2017 Apr; 5(7):. PubMed ID: 28364032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
